Cerdulatinib yields 'encouraging' results in CTCL, PTCL
4 Lượt xem
• 08/09/23
0
0
Nhúng
administrator
Người đăng ký
The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas. In a phase 2 trial, cerdulatinib produced responses in 34% of patients with peripheral T-cell lymphoma (PTCL) and 26% of those with cutaneous T-cell lymphoma (CTCL). Learn more at www.mdedge.com/hematology-oncology.
Cho xem nhiều hơn
Bình luận trên Facebook
SORT BY-
Nhận xét hàng đầu
-
Bình luận mới nhất